
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1354214/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	0.8	270
2	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology, 2018, 20, 123-131.	0.6	184
3	Sirolimus for the treatment of children with various complicated vascular anomalies. European Journal of Pediatrics, 2015, 174, 1579-1584.	1.3	177
4	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HITâ€~91. European Journal of Cancer, 2009, 45, 1209-1217.	1.3	173
5	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-Oncology, 2011, 13, 669-679.	0.6	149
6	Incidence of atypical teratoid/rhabdoid tumors in children. Cancer, 2010, 116, 5725-5732.	2.0	126
7	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	0.8	121
8	Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatric Blood and Cancer, 2009, 53, 1171-1179.	0.8	99
9	Prospective evaluation of late effects after childhood cancer therapy with a follow-up over 9 years. European Journal of Pediatrics, 2000, 159, 750-758.	1.3	79
10	Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro-Oncology, 2013, 15, 224-234.	0.6	69
11	Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. Journal of Neurosurgery: Pediatrics, 2010, 6, 137-144.	0.8	64
12	Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opinion on Pharmacotherapy, 2008, 9, 301-309.	0.9	58
13	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. Journal of Clinical Oncology, 2020, 38, 2028-2040.	0.8	58
14	Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. Journal of Neuro-Oncology, 2006, 78, 199-205.	1.4	52
15	Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). Journal of Neuro-Oncology, 2005, 72, 179-183.	1.4	49
16	Low-Dose Versus High-Dose Immunoglobulin for Primary Treatment of Acute Immune Thrombocytopenic Purpura in Children: Results of a Prospective, Randomized Single-Center Trial. Journal of Pediatric Hematology/Oncology, 2003, 25, 797-800.	0.3	45
17	Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents—a single centre experience of 20Âyears. Annals of Hematology, 2018, 97, 989-998.	0.8	45
18	Spinal cord ependymomas in children and adolescents. Child's Nervous System, 2012, 28, 2017-2028.	0.6	39

#	Article	IF	CITATIONS
19	Treatment of Children With Central Nervous System Primitive Neuroectodermal Tumors/Pinealoblastomas in the Prospective Multicentric Trial HIT 2000 Using Hyperfractionated Radiation Therapy Followed by Maintenance Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 863-871.	0.4	39
20	Residual or Recurrent Cerebellar Low-Grade Glioma in Children after Tumor Resection: Is Re-Treatment Needed? A Single Center Experience from 1983 to 2003. Pediatric Neurosurgery, 2006, 42, 159-164.	0.4	33
21	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	0.6	33
22	Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. Clinical Cancer Research, 2017, 23, 4224-4232.	3.2	33
23	A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning. Child's Nervous System, 2009, 25, 173-181.	0.6	32
24	The genetic tumor background is an important determinant for heterogeneous <i>MYCN</i> â€amplified neuroblastoma. International Journal of Cancer, 2016, 139, 153-163.	2.3	32
25	Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. Journal of Antimicrobial Chemotherapy, 2014, 69, 2522-2526.	1.3	31
26	Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol. European Journal of Cancer, 2015, 51, 2434-2443.	1.3	30
27	Outcome and Long-Term Side Effects after Synchronous Radiochemotherapy for Childhood Brain Stem Gliomas. Pediatric Neurosurgery, 2001, 35, 173-180.	0.4	27
28	Feasibility and Toxicity of Intrathecal Liposomal Cytarabine in 5 Children and Young Adults With Refractory Neoplastic Meningitis. Journal of Pediatric Hematology/Oncology, 2007, 29, 222-226.	0.3	27
29	Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anti-Cancer Drugs, 2009, 20, 794-799.	0.7	27
30	Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation. European Journal of Haematology, 2006, 76, 526-530.	1.1	26
31	Gastrointestinal stromal tumours in children and young adults: A clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). European Journal of Cancer, 2011, 47, 1692-1698.	1.3	26
32	Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature. Journal of Neuro-Oncology, 2011, 104, 279-286.	1.4	24
33	Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes. Pediatric Blood and Cancer, 2016, 63, 611-617.	0.8	22
34	Fatal Evans' syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. European Journal of Haematology, 2004, 72, 444-447.	1.1	20
35	CLINICAL, RADIOLOGICAL, AND PATHOLOGICAL FINDINGS IN FOUR CHILDREN WITH GASTROINTESTINAL STROMAL TUMORS OF THE STOMACH. Pediatric Hematology and Oncology, 2007, 24, 209-219.	0.3	19
36	Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Annals of Hematology, 2008, 87, 887-890.	0.8	19

#	Article	IF	CITATIONS
37	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Oncologist, 2019, 24, e921-e929.	1.9	19
38	A very rare cancer in Down syndrome: medulloblastoma. Epidemiological data from 13 countries. Journal of Neuro-Oncology, 2013, 112, 107-114.	1.4	18
39	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. Journal of Neuro-Oncology, 2016, 128, 463-471.	1.4	18
40	Clinical and histopathological findings in two Turkish children with follicular bronchiolitis. European Journal of Pediatrics, 2001, 160, 223-226.	1.3	17
41	Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses. International Journal of Antimicrobial Agents, 2017, 50, 272-275.	1.1	17
42	The Iceberg Map of germline mutations in childhood cancer. Current Opinion in Pediatrics, 2018, 30, 855-863.	1.0	16
43	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. Strahlentherapie Und Onkologie, 2021, 197, 674-682.	1.0	16
44	Recurrent lower respiratory tract infections in a 14-year-old boy with tracheobronchomegaly (Mounier-Kuhn syndrome). , 2000, 29, 476-479.		15
45	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. Child's Nervous System, 2016, 32, 2439-2446.	0.6	15
46	Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). European Journal of Cancer, 2021, 142, 112-122.	1.3	15
47	Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups. Journal of Neuro-Oncology, 2013, 111, 337-345.	1.4	14
48	Long-term Remission in a Female With Multiple Relapsed Juvenile Granulosa Cell Tumor. Journal of Pediatric Hematology/Oncology, 2015, 37, e486-e489.	0.3	14
49	The Phenotype and Treatment of WIP Deficiency: Literature Synopsis and Review of a Patient With Pre-transplant Serial Donor Lymphocyte Infusions to Eliminate CMV. Frontiers in Immunology, 2018, 9, 2554.	2.2	14
50	Letermovir in paediatric HSCT recipients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2820-2821.	1.3	14
51	A suggestion to introduce the diagnosis of "diffuse midline glioma of the pons, H3 K27 wildtype (WHO) Tj	ETQq1_1 0.	784314 rgB⊺ 13
52	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. Advances in Radiation Oncology, 2020, 5, 1158-1169.	0.6	13
53	Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort. Pediatric Blood and Cancer, 2020, 67, e28022.	0.8	12
54	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	3.9	12

#	Article	IF	CITATIONS
55	The Immune Deficiency and Dysregulation Activity (IDDA2.1 â€~Kaleidoscope') Score and Other Clinical Measures in Inborn Errors of Immunity. Journal of Clinical Immunology, 2022, 42, 484-498.	2.0	12
56	Novel phenotypes observed in patients with <i>ETV6</i> -linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor. Journal of Medical Genetics, 2020, 57, 427-433.	1.5	11
57	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, 1689-1699.	0.6	11
58	Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults. Journal of Neuro-Oncology, 1998, 39, 71-80.	1.4	10
59	Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma. Cells, 2021, 10, 301.	1.8	10
60	Characteristics, management, and outcome of pediatric patients with postâ€ŧransplant lymphoproliferative disease—A 20 years' experience from Austria. Cancer Reports, 2021, 4, e1375.	0.6	10
61	A Profound Basic Characterization of elFs in Gliomas: Identifying elF3I and 4H as Potential Novel Target Candidates in Glioma Therapy. Cancers, 2021, 13, 1482.	1.7	9
62	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. Neuro-Oncology, 2021, 23, 1148-1162.	0.6	9
63	Is primitive neuroectodermal tumor of the kidney a distinct entity?. , 1998, 82, 1414-1415.		8
64	Atypical extraosseous Ewing sarcoma of the spinal canal with bone marrow involvement in a two-month-old boy. , 1999, 32, 471-473.		7
65	Management of children and adolescents with gray zone lymphoma: A case series. Pediatric Blood and Cancer, 2020, 67, e28206.	0.8	7
66	Interdisciplinary Radical "En-Bloc―Resection of Ewing Sarcoma of the Chest Wall and Simultaneous Chest Wall Repair Achieves Excellent Long-Term Survival in Children and Adolescents. Frontiers in Pediatrics, 2021, 9, 661025.	0.9	7
67	Hepatoblastoma in molecularly defined, congenital diseases. American Journal of Medical Genetics, Part A, 2022, 188, 2527-2535.	0.7	7
68	Medulloblastoma in a child with down syndrome: Longâ€ŧerm remission with multimodality treatment. Pediatric Blood and Cancer, 2009, 53, 1150-1151.	0.8	6
69	Peripheral Blood Stem Cell Mobilisation with Pegfilgrastim Versus Filgrastim in Children and Adolescents. Blood, 2008, 112, 4314-4314.	0.6	6
70	Mediastinal yolk sac tumor ten years after treatment of intracranial germinoma. Medical and Pediatric Oncology, 2003, 40, 54-56.	1.0	5
71	Immune Thrombocytopenia in Two Unrelated Fanconi Anemia Patients ââ,¬â€œ A Mere Coincidence?. Frontiers in Pediatrics, 2015, 3, 50.	0.9	5
72	Minimally Invasive Surgery for Pediatric Adrenal Masses—Report on Four Cases. European Journal of Pediatric Surgery Reports, 2019, 07, e75-e78.	0.1	5

#	Article	IF	CITATIONS
73	Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma—an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial. Strahlentherapie Und Onkologie, 2022, 198, 282-290.	1.0	4
74	Stem cell transplantation for patients with Evans syndrome. Expert Review of Clinical Immunology, 2009, 5, 341-348.	1.3	3
75	Case reports. Indian Pediatrics, 2011, 48, 479-486.	0.2	3
76	Secondary Solid Malignancies After High-Grade Glioma Treatment in Pediatric Patients. Pediatric Hematology and Oncology, 2015, 32, 467-473.	0.3	3
77	Successful Treatment with SCIG of a Child with Refractory Chronic ITP. Journal of Clinical Immunology, 2019, 39, 19-22.	2.0	2
78	Rapidly involuting congenital hemangioma of the liver in a newborn with incomplete Pentalogy of Cantrell: description of a new association. Journal of Surgical Case Reports, 2021, 2021, rjab047.	0.2	2
79	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	1.4	2
80	Five-Month Marrow Aplasia in a Child With Refractory Acute Myeloid Leukemia. Journal of Pediatric Hematology/Oncology, 2005, 27, 236-238.	0.3	1
81	How far should we go with cost-utility analysis when treating children with acute idiopathic thrombocytopenic purpura?. Pediatric Blood and Cancer, 2008, 50, 433-433.	0.8	1
82	Enterovirus infections in pediatric hematologic/oncologic patients. Pediatric Blood and Cancer, 2019, 66, e27448.	0.8	1
83	Immunological recovery following HLAâ€matched CD3+ TCR αß+/CD19+ depleted hematopoietic stem cell transplantation in children. Pediatric Transplantation, 2022, , e14285.	0.5	1
84	HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials Neuro-Oncology, 2022, 24, i63-i64.	0.6	1
85	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	0.6	1
86	PNR-09EVALUATION OF AGE-DEPENDENT TREATMENT STRATEGIES FOR CHILDREN AND YOUNG ADULTS WITH PINEOBLASTOMA: ANALYSIS OF POOLED SIOP-E AND HEAD START DATA. Neuro-Oncology, 2016, 18, iii8.3-iii8.	0.6	0
87	Lebenslanges Lernen. Padiatrie Und Padologie, 2017, 52, 125-125.	1.0	0
88	LGG-15. REQUIREMENT OF ADJUVANT TREATMENT IN CHILDHOOD LOW GRADE GLIOMAS (LGG) OF THE SPINAL CORD: EXPERIENCES FROM THE GERMAN LGG STUDY GROUP. Neuro-Oncology, 2018, 20, i107-i107.	0.6	0
89	Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94. Cancers, 2021, 13, 572.	1.7	0
90	EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS & amp;lt;12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. Neuro-Oncology, 2020, 22, iii309-iii309.	0.6	0

#	Article	IF	CITATIONS
91	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN'S HAEMATOLOGY/ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii315-iii315.	0.6	0
92	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL. Neuro-Oncology, 2020, 22, iii389-iii390.	0.6	0
93	MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?. Neuro-Oncology, 2020, 22, iii389-iii389.	0.6	0
94	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. Neuro-Oncology, 2021, 23, vi122-vi122.	0.6	0
95	RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort. Neuro-Oncology, 2022, 24, i11-i12.	0.6	0
96	ATRT-04. Clinical and (epi)genetic characterisation of patients with atypical teratoid/rhabdoid tumor (ATRT) and extracranial malignant rhabdoid tumor conceived following assisted reproduction technologies (ART). Neuro-Oncology, 2022, 24, i2-i2.	0.6	0
97	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. Neuro-Oncology, 2022, 24, i42-i43.	0.6	0
98	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. Neuro-Oncology, 2022, 24, i113-i113.	0.6	0
99	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. Neuro-Oncology, 2022, 24, i114-i115.	0.6	0
100	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	0.6	0
101	HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study Neuro-Oncology, 2022, 24, i67-i67.	0.6	0
102	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and without <i>NF2</i> mutation. Neuro-Oncology, 2022, 24, i44-i45.	0.6	0
103	MEDB-16. Persistent radiological lesions at the end of primary therapy in childhood medulloblastoma: residual lesion or active residual tumor?. Neuro-Oncology, 2022, 24, i108-i108.	0.6	0
104	EPEN-06. Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. Neuro-Oncology, 2022, 24, i39-i39.	0.6	0
105	Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia – a Population-Based Analysis of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Pediatric Hematology and Oncology 0 1-11	0.3	Ο